Radiotherapy & Oncology
Volume 90, Issue 1 , Pages 74-79, January 2009

High local recurrence risk is not associated with large survival reduction after postmastectomy radiotherapy in high-risk breast cancer: A subgroup analysis of DBCG 82 b&c

  • Marianne Kyndi

      Affiliations

    • Department of Experimental Clinical Oncology, Aarhus University Hospital, Denmark
    • Department of Pathology, Aarhus University Hospital, Denmark
    • Corresponding Author InformationCorresponding author. Department of Experimental Clinical Oncology, Aarhus University Hospital, Århus Sygehus, Noerrebrogade 44, Building 5, 2, DK-8000 Aarhus C, Denmark.
  • ,
  • Marie Overgaard

      Affiliations

    • Department of Oncology, Århus University Hospital, Denmark
  • ,
  • Hanne M. Nielsen

      Affiliations

    • Department of Experimental Clinical Oncology, Aarhus University Hospital, Denmark
  • ,
  • Flemming B. Sørensen

      Affiliations

    • Department of Pathology, Aarhus University Hospital, Denmark
  • ,
  • Helle Knudsen

      Affiliations

    • Department of Pathology, Herlev Hospital, Denmark
  • ,
  • Jens Overgaard

      Affiliations

    • Department of Experimental Clinical Oncology, Aarhus University Hospital, Denmark

Received 26 April 2008; received in revised form 28 April 2008; accepted 28 April 2008. published online 09 May 2008.

Abstract 

Background and purpose

International consensus reports recommend postmastectomy radiotherapy only to patients at high risk of a local recurrence (LR).

Materials and methods

The present analysis included 1000 out of 3083 high-risk breast cancer patients randomly assigned to postmastectomy radiotherapy in the DBCG82 b&c trials. Tissue microarrays had been constructed and sections stained for estrogen, progesterone and HER2 receptors. Median potential follow-up time was 17years. Endpoints were LR as isolated first event, breast cancer mortality and overall mortality.

Results

Among patients randomly assigned to not receive radiotherapy, three prognostic subgroups of LR risk were found. “The good” defined by at least four out of five favorable criteria (⩽3 positive nodes, tumor size <2cm, Grade 1 malignancy, estrogen or progesterone receptor positive, HER2 negative), “the Poor” defined by at least two out of three un-favorable criteria (>3 positive nodes, tumor size >5cm, Grade 3 malignancy) and finally “the Intermediate” the group in between. The smallest absolute reduction in 5-year LR probability (11%) after radiotherapy was seen for the good prognosis group. A similar absolute reduction in 15-year breast cancer mortality after radiotherapy (11%) was seen. The largest absolute reduction in 5-year LR probability after radiotherapy was seen for the poor prognosis group (36%). However, this large LR reduction did not translate into any reduction in 15-year breast cancer mortality (0%).

Conclusion

Translation of LR reduction into breast cancer mortality reduction after postmastectomy radiotherapy to high-risk breast cancer patients seems to be heterogeneous, with the largest translation occurring within the good prognosis group.

Abbreviations: CMF, cyclophosphamide methotrexate fluorouracil, CT, computer tomography, DBCG, Danish Breast Cancer Cooperative Group, DM, distant metastases, EBCTCG, Early Breast Cancer Trialists Collaborative Group, ER, estrogen receptor, PgR, progesterone receptor, LR, local recurrence, PMRT, Postmastectomy radiotherapy, TNM, tumor node metastasis

Keywords: Breast cancer, Local recurrence, Postmastectomy radiotherapy, Randomized study, Tissue microarray

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 The study was conducted on behalf of the DBCG (Danish Breast Cancer Cooperative Group).

PII: S0167-8140(08)00235-1

doi:10.1016/j.radonc.2008.04.014

Radiotherapy & Oncology
Volume 90, Issue 1 , Pages 74-79, January 2009